Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

How New Antibody Treatments Could Improve Your Health

Kyungdong Pharmaceutical has announced a significant milestone in the development of a biosimilar antibody candidate, thanks to its collaboration with Asimov, a company specializing in AI-driven synthetic biology. This partnership has successfully created a high-performing production cell line, which is essential for the large-scale manufacturing and future commercialization of this next-generation therapeutic. The achievement is a crucial step in Kyungdong’s expansion into the biologics market, where they aim to enhance treatment options for patients globally.

For individuals interested in healthy aging, this development could lead to more accessible and effective treatments for various conditions, including those related to cardiovascular, gastrointestinal, and respiratory health. By advancing biosimilar therapies, which are designed to be similar to already approved biologic medications, Kyungdong Pharmaceutical aims to improve patient outcomes while potentially lowering treatment costs. This could mean better access to high-quality medications for you and others looking to manage health conditions effectively as they age.

The research is still in the early stages, focusing on cell line development and production capabilities. While this is a promising step, it is important to note that the biosimilar antibody is not yet available for public use, and further research and development will be necessary before it can be commercialized. The collaboration showcases the potential of combining advanced technology with pharmaceutical expertise, paving the way for innovative treatments in the future.

As this field evolves, staying informed about new therapeutic developments may help you make better health choices. Engaging with healthcare providers about emerging treatments can ensure you have access to the latest options for maintaining your health as you age.

Source